Testing a new drug for certain blood and solid tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- For lymphoma: you can be more tired or weak (ECOG 0-2); for solid tumors: you must be fairly active (ECOG 0-1)
- Your cancer has come back or not responded to at least 2 past treatments (for lymphoma)
- You need to provide a sample of your tumor tissue for testing
- You must have at least one tumor that can be measured on scans
- You must have recovered from side effects of previous treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
This study tests a new cancer drug called HDM2024 in people with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have stopped responding to standard treatments. The drug is designed to target specific proteins called EGFR and HER3 on cancer cells.
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Hear when a new Refractory Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.